Reduced raltegravir clearance in HIV-infected liver transplant recipients

An unexpected interaction with immunosuppressive therapy?

Dario Cattaneo, Massimo Puoti, Salvatore Sollima, Cristina Moioli, Caterina Uberti Foppa, Sara Baldelli, Emilio Clementi, Cristina Gervasoni

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objectives: Liver transplantation (LTx) is considered a safe procedure in selected HIV-infected patients. In this clinical setting raltegravir is the antiretroviral of choice due to its optimal tolerability and its negligible interactions with immunosuppressive drugs. We aimed at providing data on the pharmacokinetics of raltegravir in LTx recipients, on which the available information is inconclusive. Methods: In this retrospective multicentre study we characterized the pharmacokinetics of raltegravir in a consecutive series of HIV-infected LTx recipients referred to our laboratory for therapeutic drug monitoring (TDM) and compared the obtained profiles with those collected from a control group of HIV-infected patients. Results: Seventeen HIV-infected LTx patients were considered. LTx recipients had significantly higher raltegravir AUC0-12 compared with the control group of HIV-infected patients [14314 (11627-19998) versus 8795 (5218- 12954) ng.h/mL; P

Original languageEnglish
Article numberdkv466
Pages (from-to)1341-1345
Number of pages5
JournalJournal of Antimicrobial Chemotherapy
Volume71
Issue number5
DOIs
Publication statusPublished - May 1 2016

Fingerprint

Immunosuppressive Agents
HIV
Liver
Pharmacokinetics
Therapeutics
Control Groups
Drug Monitoring
Liver Transplantation
Multicenter Studies
Retrospective Studies
Raltegravir Potassium
Transplant Recipients
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Reduced raltegravir clearance in HIV-infected liver transplant recipients : An unexpected interaction with immunosuppressive therapy? / Cattaneo, Dario; Puoti, Massimo; Sollima, Salvatore; Moioli, Cristina; Foppa, Caterina Uberti; Baldelli, Sara; Clementi, Emilio; Gervasoni, Cristina.

In: Journal of Antimicrobial Chemotherapy, Vol. 71, No. 5, dkv466, 01.05.2016, p. 1341-1345.

Research output: Contribution to journalArticle

Cattaneo, Dario ; Puoti, Massimo ; Sollima, Salvatore ; Moioli, Cristina ; Foppa, Caterina Uberti ; Baldelli, Sara ; Clementi, Emilio ; Gervasoni, Cristina. / Reduced raltegravir clearance in HIV-infected liver transplant recipients : An unexpected interaction with immunosuppressive therapy?. In: Journal of Antimicrobial Chemotherapy. 2016 ; Vol. 71, No. 5. pp. 1341-1345.
@article{0717e4c937e346dd802c0826945bafab,
title = "Reduced raltegravir clearance in HIV-infected liver transplant recipients: An unexpected interaction with immunosuppressive therapy?",
abstract = "Objectives: Liver transplantation (LTx) is considered a safe procedure in selected HIV-infected patients. In this clinical setting raltegravir is the antiretroviral of choice due to its optimal tolerability and its negligible interactions with immunosuppressive drugs. We aimed at providing data on the pharmacokinetics of raltegravir in LTx recipients, on which the available information is inconclusive. Methods: In this retrospective multicentre study we characterized the pharmacokinetics of raltegravir in a consecutive series of HIV-infected LTx recipients referred to our laboratory for therapeutic drug monitoring (TDM) and compared the obtained profiles with those collected from a control group of HIV-infected patients. Results: Seventeen HIV-infected LTx patients were considered. LTx recipients had significantly higher raltegravir AUC0-12 compared with the control group of HIV-infected patients [14314 (11627-19998) versus 8795 (5218- 12954) ng.h/mL; P",
author = "Dario Cattaneo and Massimo Puoti and Salvatore Sollima and Cristina Moioli and Foppa, {Caterina Uberti} and Sara Baldelli and Emilio Clementi and Cristina Gervasoni",
year = "2016",
month = "5",
day = "1",
doi = "10.1093/jac/dkv466",
language = "English",
volume = "71",
pages = "1341--1345",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Reduced raltegravir clearance in HIV-infected liver transplant recipients

T2 - An unexpected interaction with immunosuppressive therapy?

AU - Cattaneo, Dario

AU - Puoti, Massimo

AU - Sollima, Salvatore

AU - Moioli, Cristina

AU - Foppa, Caterina Uberti

AU - Baldelli, Sara

AU - Clementi, Emilio

AU - Gervasoni, Cristina

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Objectives: Liver transplantation (LTx) is considered a safe procedure in selected HIV-infected patients. In this clinical setting raltegravir is the antiretroviral of choice due to its optimal tolerability and its negligible interactions with immunosuppressive drugs. We aimed at providing data on the pharmacokinetics of raltegravir in LTx recipients, on which the available information is inconclusive. Methods: In this retrospective multicentre study we characterized the pharmacokinetics of raltegravir in a consecutive series of HIV-infected LTx recipients referred to our laboratory for therapeutic drug monitoring (TDM) and compared the obtained profiles with those collected from a control group of HIV-infected patients. Results: Seventeen HIV-infected LTx patients were considered. LTx recipients had significantly higher raltegravir AUC0-12 compared with the control group of HIV-infected patients [14314 (11627-19998) versus 8795 (5218- 12954) ng.h/mL; P

AB - Objectives: Liver transplantation (LTx) is considered a safe procedure in selected HIV-infected patients. In this clinical setting raltegravir is the antiretroviral of choice due to its optimal tolerability and its negligible interactions with immunosuppressive drugs. We aimed at providing data on the pharmacokinetics of raltegravir in LTx recipients, on which the available information is inconclusive. Methods: In this retrospective multicentre study we characterized the pharmacokinetics of raltegravir in a consecutive series of HIV-infected LTx recipients referred to our laboratory for therapeutic drug monitoring (TDM) and compared the obtained profiles with those collected from a control group of HIV-infected patients. Results: Seventeen HIV-infected LTx patients were considered. LTx recipients had significantly higher raltegravir AUC0-12 compared with the control group of HIV-infected patients [14314 (11627-19998) versus 8795 (5218- 12954) ng.h/mL; P

UR - http://www.scopus.com/inward/record.url?scp=84965022943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965022943&partnerID=8YFLogxK

U2 - 10.1093/jac/dkv466

DO - 10.1093/jac/dkv466

M3 - Article

VL - 71

SP - 1341

EP - 1345

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 5

M1 - dkv466

ER -